Updated January 2012
Clinicians providing services to HIV-infected transgender patients should integrate transgender treatment recommendations and standards of care into their practice. (AII)
Clinicians caring for HIV-infected patients may encounter individuals whose experienced gender does not conform to his/her natally assigned sex. These guidelines use the term transgender to refer to a broad range of nonconforming gender identities.
Some patients may be unsure of their gender identity and may not have had opportunities to discuss their concerns with a medical professional. Others may have a highly developed gender identity and may request hormone therapy or may already be receiving hormones that are obtained either by prescription or illicitly without a prescription.
Many HIV-infected transgender patients avoid healthcare providers because they fear insensitive treatment or have perceptions of being judged. Some of these patients also may have had poor interactions with previous providers. Providing a spectrum of care may help patients overcome resistance to treatment if these services are provided in a nonjudgmental manner. These services include:
- HIV-related medical care that includes HIV prevention and harm reduction counseling
- Mental health and substance use screening and services
- Transgender-specific care, such as hormone therapy and case management services
As part of transgender-specific care, clinicians should integrate treatment recommendations and standards of care for transgender patients into their practice. For information regarding transgender standards of care, see Section X: Transgender-Related Standards of Care and Referral Resources.
Provision of transgender-related services in one setting is optimal. However, if such treatment integration is not possible, the clinician should make appropriate referrals for necessary specialized services, including transgender-related healthcare, community resources, and legal services (see Section X: Transgender-Related Standards of Care and Referral Resources).
Specific epidemiologic data for HIV-infected transgender individuals are lacking. However, a review of available data reported a mean HIV prevalence of 27.7% in male-to-females (MtFs) in four studies where HIV testing was performed in this population.1 Seroprevalence was highest among black MtFs, with a mean estimate of 56.3%.1 An HIV prevalence rate of 68% among MtF sex workers was also reported in a small sample population.1 Limited data suggest that HIV prevalence rates among female-to-males (FtMs) is low, but their self-reported sexual risk behaviors suggest an increased risk for HIV infection compared with the general population.1
III. TRANSGENDER-RELATED TERMINOLOGY
Knowledge of transgender-related terminology is important for awareness and effective communication with transgender patients. Table 1 provides an overview of commonly used transgender-related terms.
Gender identity is distinct from sexual orientation. Sexual orientation involves sexual attraction, whereas gender identity involves the individual’s natal sex in relation to the gender that he/she experiences.
Like all people, transgender individuals present with a variety of sexual orientations and behaviors. The terms gay, straight, lesbian, homosexual, and heterosexual may be defined differently by transgender individuals, depending on whether they are using their natal anatomy or their gender identity as a reference point. As with all people, these terms may be more about identity than behavior. Therefore, assessment of a patient’s gender identity is distinct from assessment of his/her sexual behavior (see Section VIII: Risk and Harm-Reduction Approach for HIV-Infected Transgender Patients).
IV. BASELINE HISTORY AND PSYCHOSOCIAL ASSESSMENT
As part of the routine management of HIV-infected patients, clinicians should perform a psychosocial assessment at baseline and at least annually in HIV-infected transgender patients. (AIII)
A psychosocial assessment is used to identify not only the transgender patient’s basic psychosocial information but also circumstances that may require transgender-related case management services (see Table 2). Some patients may feel stigmatized or victimized by family members, coworkers, or employers. Such negative experiences often destabilize patients and can be barriers to HIV treatment.
A patient’s responses to a psychosocial assessment may also increase the clinician’s awareness of transgender-related culture, advocacy organizations, and social networks.
For more information about psychosocial assessment, refer to the Mental Health Quick Reference Card.
V. ROUTINE SCREENING AND LABORATORY ASSESSMENTS FOR HIV-INFECTED TRANSGENDER PATIENTS
Routine medical screening of HIV-infected transgender patients should be performed according to standards of care, as determined by clinical judgment and according to the patient’s level of comfort. (AIII) For recommendations on cancer and cardiovascular screening for patients receiving hormone therapy, see Section VI. A: Hormone Therapy.
Most aspects of routine medical screening in transgender patients are similar to those in the general population. However, transgender patients, regardless of their surgical status, may find aspects of a physical examination distressing or traumatic, particularly breast, genital, pelvic, and rectal examinations. When immediate examination is not clinically indicated, examination deferral can be offered until the patient expresses readiness. Deferral of examinations to increase patient comfort should be documented in the medical record. An ongoing dialogue about the patient’s concerns, as well as offering examination deferral when appropriate, may convey respect for the patient. Patients who perceive respect and encouragement from their care providers may be more proactive about their health and remain in care (see Table 3).6
A. Pelvic Examination
Clinicians should perform routine pelvic examinations in HIV-infected FtM patients and MtF patients who have undergone complete sex reassignment surgery according to HIV care guidelines for natal females. Before performing a pelvic examination in transgender patients, clinicians should explain the medical reasons for the examination. (AIII)
HIV-infected FtM patients remain at risk for gynecologic complications that can be detected by routine pelvic examinations (see Primary Care Approach to the HIV-Infected Patient).
B. Cytologic Screening
Clinicians should perform routine cervical Pap tests in any HIV-infected FtM patient with cervical tissue; patients who are uncomfortable receiving a Pap test should be educated about the importance of obtaining cervical cytology. (AIII)
Clinicians should notify the pathologist when submitting a Pap test sample from a FtM patient who is receiving testosterone therapy because testosterone-related atrophy of the cervix may mimic cervical dysplasia.7 (AIII)
Neovaginal Pap tests are not indicated for HIV-infected MtF patients. (AIII)
FtM patients should receive routine cervical Pap testing if cervical tissue is present, regardless of whether they have undergone a hysterectomy.
FtM patients receiving testosterone therapy may experience atrophy of the cervix, which can mimic cervical dysplasia.7 Notifying the pathologist of the patient’s testosterone treatment status can increase accuracy of Pap test results.
For transgender patients, the smallest, clinically indicated speculum may be necessary for a Pap test. For information regarding Pap screening, refer to Cervical Dysplasia and Cancer.
C. Screening for Gonococcal and Chlamydial Infections
Clinicians should screen HIV-infected transgender patients at baseline for gonorrhea and chlamydia; screening should also be performed at least annually thereafter for sexually active HIV-infected transgender patients. (AIII)
Clinicians should test all possible sites of exposure when screening for gonorrhea and chlamydia, including the urethra, rectum, and pharynx. (AIII)
For additional information regarding gonococcal and chlamydial infections in HIV-infected patients, refer to the Gonococcal and Chlamydial Infections guidelines.
VI. CROSS-GENDER THERAPY FOR HIV-INFECTED TRANSGENDER PATIENTS
Cross-gender therapy is used to physically transition transgender patients and may include hormone therapy alone or hormone therapy and physical enhancements, such as breast enlargement or complete gender reassignment surgery. Cross-gender therapy provides the opportunity to greatly increase quality of life for transgender patients by physically affirming their gender identity. For clinicians caring for HIV-infected transgender patients, cross-gender therapy may also facilitate retention in HIV care. However, both hormone therapy and gender reassignment surgery require careful consideration, as well as patient education, to optimize safety and reduce health risks associated with these forms of treatment, including infertility.
A. Hormone Therapy
Clinicians should educate HIV-infected transgender patients about the possible health risks associated with hormone therapy. (AIII)
Although several small retrospective cohort studies suggest hormone therapy is generally safe, particularly over the short- and midterm,8 limited data exist on the long-term effects of cross-gender hormone therapy. Clinicians should inform patients that hormone therapy may increase the risk for:
- Cardiovascular disease—particularly venous thromboembolism
- Certain cancers—including breast, ovarian, and uterine cancers
- Hepatic complications—due to disturbances in liver metabolism caused by elevated liver enzymes
- Erectile dysfunction—due to increased circulating estrogen, which may also increase the risk for HIV transmission as a result of condom slippage or reduced condom use
Hormone treatment for transgender patients is most effective when clinicians provide therapy according to the fundamental principles listed in Table 4.
1. Concomitant Hormone Therapy and ART
Hormone therapy for HIV-infected transgender patients who are not initiating or receiving ART should be prescribed according to the same standards of care for all transgender patients. (AIII)
Before prescribing hormone therapy for HIV-infected transgender patients who are receiving
ART, clinicians should (AIII):
- Consult with, or refer patients, to a provider who has experience in prescribing both hormone therapy and ART to select appropriate hormone treatment
- Educate patients about the prescribing considerations, including hormone selection and dose, for optimizing the effects of hormone therapy when prescribed in conjunction with an ART regimen
- Discuss the importance of adherence to ART with patients, including the risks associated with dangerously high circulating hormone levels due to ART interruption
Clinicians should monitor hormone therapy in HIV-infected transgender patients according to established guidelines for all transgender patients. (AIII)
The clinician’s selection of hormone and dose depends on whether or not the patient is also receiving ART. For ART-naïve patients who are not initiating ART, hormone therapy can be provided in the primary care setting according to standard guidelines for all transgender patients, such as the guidelines published by the Endocrine Society.10 Hormone therapy can also be provided through referral to another provider or an endocrinologist with expertise in transgender treatment. See Section X: Transgender-Related Standards of Care and Referral Resources for medical referral resources for transgender patients.
Hormone therapy for patients initiating or already receiving ART requires a careful approach. Some transgender patients may decline ART because of concerns about reduced hormone levels when prescribed with HIV-related medications.
Educating patients about how hormone selection and dose can reduce interactions between hormones and ART may encourage acceptance of ART from those who would otherwise decline it.
When hormone adjustments are made because of concomitant ART, concentrations of circulating hormone can become dangerously high if a patient does not adhere to ART. Severe cardiovascular complications, including stroke, deep vein thrombosis, and pulmonary embolism, may occur. Therefore, clinicians should consult with, or refer patients to, a provider who has experience in prescribing both hormone therapy and ART to select appropriate hormone treatment. Clinicians should also emphasize the risks associated with increased hormone levels when discussing the importance of adherence to ART.
Cross-gender hormone monitoring for HIV-infected transgender patients is the same as for all transgender patients. Established monitoring guidelines, such as those by the Endocrine Society,10 should be used.
2. Cancer Screening and Hormone Therapy
Clinicians should perform breast cancer screening in the following HIV-infected transgender patients according to clinical judgment and consideration of current guidelines established for natal females of the same age (see Appendix A):
- FtM patients with remaining breast tissue (AIII)
- MtF transgender patients with breast tissue who have received hormone therapy for at least 5 years (AIII)
MtF patients receiving feminizing hormones may be at increased risk for developing breast cancer in comparison with natal males. Although the risk is likely lower for MtF patients than it is for natal females,11 clinicians should educate MtF patients receiving feminizing hormones about the increased risk for breast cancer and about breast cancer screening. Screening should be performed for MtF patients who have received hormone therapy for at least 5 years and should be based on clinical judgment and consideration of current guidelines for natal females of the same age (see Appendix A).
The risk for breast cancer is reduced in FtM patients who have undergone chest reconstruction, including reduction or mastectomy. However, clinicians should inform patients that the risk is still present when breast tissue remains and should perform screening according to clinical judgment and consideration of current guidelines for natal females of the same age (see Appendix A).
Clinicians should perform digital rectal examinations as part of routine HIV care for HIV-MtF transgender patients (see Primary Care Approach to the HIV-Infected Patient); clinical judgment and current guidelines for natal HIV-infected males should be used when considering prostate examinations in MtF transgender patients (see Appendix A). (AIII)
Feminizing hormone therapy may reduce the risk for prostate cancer; however, the extent of the reduction is unknown.11 Additional data are required before a transgender-specific recommendation can be established. See Appendix A for HIV-related screening recommendations.
3. Cardiovascular Disease and Hormone Therapy
When HIV-infected transgender patients choose to receive hormones, clinicians should educate them about the cardiovascular effects of hormone therapy and, when indicated, provide counseling to reduce the risk for cardiovascular disease; such discussions should take place at the time of initiation of hormone therapy and frequently thereafter. (AIII)
Both feminizing and masculinizing hormone therapies increase the risk for cardiovascular disease, including increased arterial stiffness with androgen therapy12 and venous thromboembolism and stroke with estrogen therapy.8 These effects should be discussed at the time of initiation of hormone therapy and frequently thereafter. Transgender patients receiving hormone therapy who have comorbid cardiovascular risk factors require more frequent counseling and education to reduce their risk for cardiovascular disease, including smoking (see Smoking Cessation in HIV-Infected Patients).
B. Gender-Confirming Surgery
The standards of care for gender reassignment surgery, as well as less complicated gender confirming procedures, are the same for HIV-infected transgender patients as for transgender patients who are not infected with HIV. (AIII)
Surgery, including breast implantation and gender-reassignment surgery, is not contraindicated in HIV-infected patients. (AIII)
Some HIV-infected transgender patients may elect to receive surgery as part of the transitional process. Gender-confirming surgery may involve complete gender reassignment surgery, also known as gender realignment surgery or sex reassignment surgery; or less complicated procedures, such as rhinoplasty or breast and gluteal implantation in combination with feminizing hormone therapy. In either case, the standards of care for these gender-confirming surgical procedures are the same for HIV-infected transgender patients as for transgender patients without HIV infection. Decisions regarding gender-confirming surgery should be made in consultation with a specialist in transgender surgery. See Section X: Transgender-Related Standards of Care and Referral Resources for referral resources for individuals seeking gender-confirming surgery.
VII. MENTAL HEALTH AND SUBSTANCE USE SCREENING
Clinicians should perform a mental health and substance use assessment in HIV-infected transgender patients at baseline and at least annually thereafter. (AIII)
Clinicians should refer HIV-infected transgender patients requiring mental health services to a psychiatrist or psychologist with knowledge and experience in transgender treatment. (AIII)
If the HIV-infected transgender patient’s substance use screening result is positive, or if the patient has a history of substance use, the clinician should re-evaluate the patient’s substance use at least quarterly. (AIII)
Clinicians should offer patients with active substance use/abuse problems referral to appropriate substance use treatment programs or other substance use services. (AIII)
Comorbid mental health and substance use disorders are more prevalent among HIV-infected patients13 and sexual minorities14,15 than the general population. In addition to the baseline history and psychosocial assessment, clinicians should perform mental health and substance use screening. Identification and stabilization of mental health and substance use disorders in transgender patients can help eliminate barriers to medical care, including HIV treatment, and enable patients to pursue gender transformation in a positive manner and under medical supervision.
When further assessment is warranted for transgender patients, clinicians should optimally be able to refer them to a mental health or substance use provider who is experienced with transgender care. If the clinician cannot make a direct referral, then he/she should be familiar with appropriate referral services (see Section X: Transgender-Related Standards of Care and Referral Resources). For information about mental health and substance use screening, refer to Mental Health Screening: A Quick Reference Guide for HIV Primary Care Clinicians and Screening and Ongoing Assessment for Substance Use.
VIII. RISK- AND HARM-REDUCTION APPROACH FOR HIV-INFECTED TRANSGENDER PATIENTS
Clinicians should assess for the following behaviors in HIV-infected transgender patients:
- Silicone use
- Hormones obtained without prescription, including specific hormones used
- Needle-sharing among those who inject hormones, silicone, and/or drugs
- Sexual risk behaviors
- Genital taping
Clinicians should provide risk-reduction counseling and, when appropriate, harm-reduction counseling for HIV-infected transgender patients who report potentially harmful behaviors. Patients at risk for intentionally harming their genitalia require referral for psychiatric evaluation. (AIII)
A. Silicone Use
No recommendations exist for administering silicone injections as gender-confirming treatment. However, this dangerous method for altering one’s appearance is often available at silicone parties or pumping parties. Many transgender patients may have friends who have received injections without major complications, but serious complications usually arise later. Clinicians and patients should discuss the possible consequences of silicone use, which are often not immediate.
In addition to the risk for HIV and hepatitis transmission and bacteriological infections, clinicians should emphasize the long-term risks that are commonly associated with silicone injection:
- Silicone can congeal over time, move to other parts of the body and cause subsequent disfigurement
- Silicone injected into the breast can interfere with the interpretation of mammograms, and may increase a patient’s risk for undetected cancer in the future
Life-threatening injuries are less common but can occur. Migration of the substance outside of the injection site into the blood stream (i.e., silicone embolism syndrome) can cause respiratory failure.16 Silicone used for illicit injections may be composed of materials other than medical-grade silicone.
B. Hormone Use
Some transgender patients obtain hormones without a prescription. To reduce possible interactions with HIV-related treatment, clinicians should inquire about patients’ use of nonprescribed hormones and should ask for specific information regarding the type of hormones patients are obtaining. Many clinicians will advise patients to avoid use of hormones that are obtained without a prescription and inform them of the risks associated with such behavior; however, such advice may not be acknowledged unless the provider is offering an alternative method for obtaining hormone therapy. An effective harm-reduction approach may be to encourage a reduction in the use of street hormones as the patient transitions to receiving only prescribed hormone therapy. The following are risks associated with receiving hormones that are not obtained under the care of a clinician:
- Needle-sharing increases the risk for hepatitis B, hepatitis C, and HIV transmission
- Bacterial infections can result from non-sterile technique/supplies
- Liver damage, blood clotting problems, and deep vein thrombosis can result from inconsistent hormone dosing in illicit preparations
- Some hormones that are obtained without a prescription could be harmful in themselves (e.g., risk for disfigurement from cooking oil added to the illicit preparation)
Some providers periodically assess testosterone and estradiol levels to determine whether excess concentrations of the hormones are present (CIII). However, hormone levels may not provide a clear indication of the patient’s hormone use, particularly if procurement of hormones without a prescription is inconsistent. Other laboratory markers, such as prolactin for patients receiving estrogen or hematocrit for patients receiving testosterone, may be useful for monitoring hormone effects (CIII).
C. Injection Practices
For patients who engage in high-risk injection behaviors, harm-reduction techniques can offer an effective means for modifying behaviors that place patients at risk for transmission of HIV and other diseases. For example, transgender patients who choose to continue to inject illicit hormones or silicone
should be referred to New York State’s Syringe Access Resources. Individuals seeking syringes for hormone injections should receive prescriptions for clean syringes and needles or referral to services that provide syringes appropriate for hormone injections and education about how to safely perform these injections. For additional information on sterile syringes and safer injection techniques, see Working with the Active User.
D. Sexual Risk
For all patients, a sexual risk assessment should focus on behaviors rather than the sexual orientation of the patient. In particular, the patient may not identify with the words homosexual or gay, and questions such as Are you a homosexual? or Are you gay? may not provide useful information. Clinicians should also strive to help the patient feel comfortable with providing information about his/her sexual behavior. The following could be used as part of a dialogue about sexual health:
- I want to offer you the highest quality of care possible. Understanding your sexual practices will help me provide you with better care.
- Do you have anal, oral, or vaginal sex?
- Is this sex receptive, insertive, or both?
- Do you use safer sex practices, such as wearing condoms and using dental dams?
Providers should use language that the individual patient understands. For additional information regarding risk-reduction counseling related to sexual transmission, refer to the Prevention with Positives: Integrating HIV Prevention into HIV Primary Care.
E. Genital Taping or Tucking
Some patients may attempt to hide their genitalia by taping or tucking. Taping increases the risk for urinary tract infections, as well as sores and damaged tissue, particularly when materials that can tear skin easily are used, such as duct tape. Patients whose long-term goals include sex reassignment surgery may reduce such behavior if they are educated about the reconstruction of natal genitalia to create new genitalia during sex reassignment surgery. If the clinician suspects that a patient may be at risk for intentionally harming his/her genitalia, then referral for a psychiatric evaluation is necessary.
IX. CASE MANAGEMENT FOR HIV-INFECTED TRANSGENDER PATIENTS
Case managers who provide services to HIV-infected transgender patients should:
- Develop expertise in transgender-related services, such as assisting patients with access to healthcare, assisting with adherence to medical treatment and medical appointments, and making appropriate referrals
- Closely monitor changes in contact information, housing, and psychosocial support for patients with unstable living situations
- Develop awareness of “trans-friendly” resources, including education, employment, legal aid resources, and harm-reduction programs
- Be familiar with the resources available to assist patients with obtaining a change of name and gender status on their identification and health insurance cards (AIII)
Unstable living situations or difficulties with insurance reimbursement may complicate regular access to healthcare for HIV-infected transgender patients. Such challenges require proactive case management involving familiarity with transgender-related services. Case managers with such expertise can facilitate care for transgender patients by performing the following functions:
- Closely monitor changes in contact information, housing, and psychosocial support for patients with unstable living situations
- Assist with adherence to medical treatment and appointments
- Refer patients to appropriate transgender-related resources
Access to trans-friendly programs may facilitate referrals for housing, employment, harm-reduction programs, and legal aid resources when needed (see Section X: Transgender-Related Standards of Care and Referral Resources). Case managers should be able to assist with name and gender status change for transgender patients’ identification cards and health insurance.
Members of the care team may find it beneficial to guide patients through the process of gender change before name change because changing the patient’s gender on his/her health insurance ID card may enable reimbursement for hormone treatment. This step may help prevent patients from obtaining illicit hormones. Advocacy for coordination of transgender-related health benefits may be necessary.*
Case managers can develop expertise in managing the processes described above through participation in training programs and related professional development. For organizations that can assist in transgender legal issues, see Section X: Transgender-Related Standards of Care and Referral Resources.
* Third-party reimbursement programs, including Medicaid, the New York State AIDS Drug Assistance Program (ADAP), and private insurers, may require female and male gender designations on insurance identification before payment can be issued for feminizing and masculinizing hormone therapy, respectively.
X. TRANSGENDER-RELATED STANDARDS OF CARE AND REFERRAL RESOURCES
A. Standards of Care
The most recognized transgender-related standards of care are the World Professional Association for Transgender Health (WPATH) Standards of Care, formerly known as the Harry Benjamin International Gender Dysphoria Association Standards of Care (www.wpath.org).17 This publication provides clinicians who may not be familiar with transgender treatment with a framework for many clinical decisions.
The WPATH Standards of Care Provides a comprehensive description of the “Five Elements of Treatment”: 1) diagnostic assessment, 2) psychotherapy, 3) real-life experience, 4) hormone therapy, and 5) surgical therapy. The Standards of Care also serve as a resource for related treatment information, including hormonal treatment and surgical options.
Other organizations have developed guidelines that expand on the WPATH Standards of Care; these include collaborative projects involving experts in the medical care of transgender patients and those with knowledge of the psychosocial aspects of transgender care, such as the following:
- Principles of Transgender Medicine and Surgery11
- Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice10
- Transgender Primary Medical Care: Suggested Guidelines for Clinicians in British Columbia3
B. Informational Resources
Clinicians can refer to a number of organizations for comprehensive transgender-related medical information. These organizations also provide additional transgender-related resources.
- World Professional Association for Transgender Health (formerly the Harry Benjamin International Gender Dysphoria Association): www.wpath.org
- Transgender Health Program: www.vch.ca/transhealth
- Transsexual Women’s Resources: www.annelawrence.com
- Transgender Care: www.transgendercare.com
- Callen-Lorde Community Health Center—This organization has established a set of protocols for hormone treatment of transgender individuals. To request a copy of the protocols, refer to www.callen-lorde.org
C. Referral Resources for Transgender Care and Services
Resources are available for clinicians to connect patients with a variety of transgender-related services.
- Callen-Lorde Community Health Center—This organization has established a set of protocols for hormone treatment of transgender individuals. To request a copy of the protocols, refer to www.callen-lorde.org
- Clinical Education Initiative—Provides clinical education to community-based medical providers, including providers of special populations. Refer to www.ceitraining.org
- Community Healthcare Network—Provides transgender health care and support services. Refer to www.chnnyc.org
- Gender Identity Project—Provides a network of services for the transgender community. Refer to www.gaycenter.org/gip/services
- Health &Education Alternatives for Teens—Provides transgender healthcare and support services for youth. Refer to www.heatprogram.org
- New York/New Jersey AIDS Education & Training Center—Provides training for providers who treat HIV-infected patients, including special populations. Refer to www.nynjaetc.org
- Sylvia Rivera Law Project—Provides legal services to transgender individuals. Refer to www.srlp.org
- Urban Justice Center—Provides legal services, advocacy, and community education for lesbian, gay, bisexual, and transgender youth. Refer to www.urbanjustice.org
- Transgender Legal Defense & Education Fund—Focuses on public education, direct legal services, community organizing, and public policy efforts. Refer to www.transgenderlegal.org
D. Transgender-Related Conferences
A number of transgender-related conferences take place annually. Some of these conferences include:
- Empire Conference (New York State)—Organized by TransEvents USA. Refer to www.transeventsusa.org/empire
- First Event Transgender Conference (Massachusetts)—Organized by the Tiffany Club of New England. Refer to www.tcne.org
- International Foundation for Gender Education Conference (Massachusetts)—Organized by the International Foundation for Gender Education. Refer to www.ifge.org
- Trans-Health Conference (Philadelphia)—Organized by the Mazzoni Center. Refer to www.trans-health.org
- Ct TransAdvocacy Coalition (Connecticut)—Organized by area advocacy groups in Connecticut. Refer to http://www.transadvocacy.com
- WPATH International Symposium (locations vary)—Organized by the World Professional Association for Transgender Health. Refer to http://wpath.org/events_symposium.cfm
1. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A systematic review. AIDS Behav 2008;12:1-17. [PubMed]
2. Fenway Health. Glossary of Gender and Transgender Terms. Boston, MA; January 2010 Revision. Available at: www.fenwayhealth.org
3. Feldman JL, Goldberg J. Transgender Primary Medical Care: Suggested Guidelines for Clinicians in British Columbia. Vancouver, British Columbia, Canada: Transcend Transgender Support & Education Society/Vancouver Coastal Health’s Transgender Health Program; 2006. Available at: http://transhealth.vch.ca/resources/library/tcpdocs/guidelines-primcare.pdf
4. Gender Identity Project. Trans Basics: Glossary of Terms. New York, NY: The Lesbian, Gay, Bisexual & Transgender Community Center. Available at: http://www.gaycenter.org
5. Murrill CS, Liu KL, Guilin V, et al. HIV prevalence and associated risk behaviors in New York City’s house ball community. Am J Public Health 2008;98:1074-1080. [PubMed]
6. Aujoulat I, d’Hoore W, Deccache A. Patient empowerment in theory and practice: Polysemy or cacophony? Patient Educ Couns. 2007;66:13-20. [PubMed]
7. Grynberg M, Fanchin R, Dubost G, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010;20:553-558. [PubMed]
8. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25. [PubMed]
9. National Network of Libraries of Medicine. Health Literacy. Bethesda, Md. Available at: http://nnlm.gov
10. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-3154. [PubMed]
11. Ettner, Eyler, Monstrey, eds. Principles of Transgender Medicine and Surgery. New York, NY: Haworth Press; 2007.
12. Emi Y, Adachi M, Sasaki A, et al. Increased arterial stiffness in female-to-male transsexuals treated with androgen. J Obstet Gynaecol Res 2008;34:890-897. [PubMed]
13. Walkup J, Wei W, Sambamoorthi U, et al. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q 2008;79:43-53. [PubMed]
14. Meyer IH. Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: Conceptual issues and research evidence. Psychol Bull 2003;129:674-97. [PubMed]
15. King M, Semlyen J, Tai SS, et al. A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people. BMC Psychiatry 2008;8:70. [PubMed]
16. Schmid A, Tzur A, Leshko L, et al. Silicone embolism syndrome: A case report, review of the literature, and comparison with fat embolism syndrome. Chest. 2005;127:2276-2281. [PubMed]
17. World Professional Association for Transgender Health (formerly the Harry Benjamin International Gender Dysphoria Association). WPATH Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People. Minneapolis, MN: World Professional Association for Transgender Health. Available at: www.wpath.org
APPENDIX A: AGE-APPROPRIATE DIAGNOSTIC SCREENING FOR HIV-INFECTED PATIENTS